Pharma

Danske Bank ser mulighed for mere udlodning fra Lundbeck https://proinvestor.com/investornyt/1223637/danske-bank-ser-mulighed-for-mere-udlodning-fra-lundbeck

What's Behind The 2x Jump In AbbVie Stock? https://proinvestor.com/investornyt/1208910/whats-behind-the-2x-jump-in-abbvie-stock

Madrigal's MASH drug Rezdiffra blows past estimates in Q2 https://firstwordpharma.com/story/5883184

BioArctic's Partner Eisai Says Leqembi Approved In Hong Kong For Alzheimer's Disease Treatment https://proinvestor.com/investornyt/1183677/bioarctics-partner-eisai-says-leqembi-approved-in-hong-kong-for-alzheimers-disease-treatment

Prediction: These Could Be the Best-Performing Pharmaceutical Stocks Through 2030 https://proinvestor.com/investornyt/1167710/prediction-these-could-be-the-best-performing-pharmaceutical-stocks-through-2030

Alk-Abello: Opjustering bør ikke give en allergisk reaktion hos investorerne https://www.proinvestor.com/boards/120265

After A 30% Fall In A Year Is Pfizer Stock A Better Pick Over Merck? https://www.proinvestor.com/investornyt/1139724/after-a-30-fall-in-a-year-is-pfizer-stock-a-better-pick-over-merck

Tophistorier inden for pharma/biotek: https://firstwordpharma.com/river/top-stories?nle=6593&nlc=30

Roche PE 17. ( Kurs 247,10 EPS 14,31. 9 Forward cirka det samme: "mid single digit growth" minus forventning til valuta.

ALK overtager amerikanske selskab bag hudtest https://www.proinvestor.com/investornyt/1099119/alk-overtager-amerikanske-selskab-bag-hudtest

Godmorgen

Lundbeck: Positive data fra fase 3 forsøg med Alzheimers-middel https://www.proinvestor.com/investornyt/1075006/lundbeck-positive-data-fra-fase-3-forsog-med-alzheimers-middel

LLY, ISRG, or JNJ: Which Healthcare Stock Could Generate the Best Returns? https://www.proinvestor.com/investornyt/1057064/lly-isrg-or-jnj-which-healthcare-stock-could-generate-the-best-returns

FDA Approves Pfizer-BioNTech's Updated COVID-19 Vaccine https://www.proinvestor.com/investornyt/1048339/fda-approves-pfizer-biontechs-updated-covid-19-vaccine

Medicinalkæmpen Johnson & Johnson dykkede 4 pct., efter selskabet har fået afvist en konkurs i sit datterselskab LTL Management af en føderal domstol i USA. Dommen faldt fredag og omhandler en konkursbegæring i datterselskabet, der er oprettet med henblik på at sætte en stopper for en lang række sager om kræft udløst af selskabets babypulver med talkum.

Sandoz To Launch Hyrimoz High-concentration Formulation https://www.proinvestor.com/investornyt/1008962/sandoz-to-launch-hyrimoz-high-concentration-formulation

Pfizer's marstacimab significantly lowers bleeding rates in Phase III haemophilia trial https://firstwordpharma.com/story/5745662

Astellas Pharma To Acquire Iveric Bio In $5.9 Bln Deal https://www.proinvestor.com/investornyt/976671/astellas-pharma-to-acquire-iveric-bio-in-59-bln-deal

Could This Drug News Lift AbbVie's Stock? https://www.proinvestor.com/investornyt/962700/could-this-drug-news-lift-abbvies-stock

Merck Stock Looks Better Priced Compared To Its Sector Peer https://www.proinvestor.com/investornyt/948162/merck-stock-looks-better-priced-compared-to-its-sector-peer